Insulin-like growth factor 1 (IGF-1) alters drug sensitivity of HBL100 human breast cancer cells by inhibition of apoptosis induced by diverse anticancer drugs.

@article{Dunn1997InsulinlikeGF,
  title={Insulin-like growth factor 1 (IGF-1) alters drug sensitivity of HBL100 human breast cancer cells by inhibition of apoptosis induced by diverse anticancer drugs.},
  author={Sandra E. Dunn and Rob Hardman and Frank W. Kari and Jeffrey C. Barrett},
  journal={Cancer research},
  year={1997},
  volume={57 13},
  pages={2687-93}
}
In this study, we tested the hypothesis that insulin-like growth factor-1 (IGF-1) modulates apoptosis in human breast cancer cells, HBL100, induced by diverse chemotherapeutic drugs. IGF-1 increased cell survival of HBL100 cells treated with 5-fluorouracil (antimetabolite), methotrexate (antimetabolite), tamoxifen (antiestrogen/antiproliferative), or camptothecin (topoisomerase 1 inhibitor) and after serum withdrawal. Elevated cell survival was not due to an increase in cell proliferation by… CONTINUE READING

Connections & Topics

Mentioned Connections BETA
. IGF-1 increased cell survival of HBL100 cells treated with 5-fluorouracil ( antimetabolite ) , methotrexate ( antimetabolite ) , tamoxifen ( antiestrogen / antiproliferative ) , or camptothecin ( topoisomerase 1 inhibitor ) and after serum withdrawal .
. IGF-1 increased cell survival of HBL100 cells treated with 5-fluorouracil ( antimetabolite ) , methotrexate ( antimetabolite ) , tamoxifen ( antiestrogen / antiproliferative ) , or camptothecin ( topoisomerase 1 inhibitor ) and after serum withdrawal .
. IGF-1 increased cell survival of HBL100 cells treated with 5-fluorouracil ( antimetabolite ) , methotrexate ( antimetabolite ) , tamoxifen ( antiestrogen / antiproliferative ) , or camptothecin ( topoisomerase 1 inhibitor ) and after serum withdrawal .
. IGF-1 increased cell survival of HBL100 cells treated with 5-fluorouracil ( antimetabolite ) , methotrexate ( antimetabolite ) , tamoxifen ( antiestrogen / antiproliferative ) , or camptothecin ( topoisomerase 1 inhibitor ) and after serum withdrawal .
. IGF-1 increased cell survival of HBL100 cells treated with 5-fluorouracil ( antimetabolite ) , methotrexate ( antimetabolite ) , tamoxifen ( antiestrogen / antiproliferative ) , or camptothecin ( topoisomerase 1 inhibitor ) and after serum withdrawal .
. IGF-1 increased cell survival of HBL100 cells treated with 5-fluorouracil ( antimetabolite ) , methotrexate ( antimetabolite ) , tamoxifen ( antiestrogen / antiproliferative ) , or camptothecin ( topoisomerase 1 inhibitor ) and after serum withdrawal .
. IGF-1 increased cell survival of HBL100 cells treated with 5-fluorouracil ( antimetabolite ) , methotrexate ( antimetabolite ) , tamoxifen ( antiestrogen / antiproliferative ) , or camptothecin ( topoisomerase 1 inhibitor ) and after serum withdrawal .
. IGF-1 increased cell survival of HBL100 cells treated with 5-fluorouracil ( antimetabolite ) , methotrexate ( antimetabolite ) , tamoxifen ( antiestrogen / antiproliferative ) , or camptothecin ( topoisomerase 1 inhibitor ) and after serum withdrawal .
. IGF-1 increased cell survival of HBL100 cells treated with 5-fluorouracil ( antimetabolite ) , methotrexate ( antimetabolite ) , tamoxifen ( antiestrogen / antiproliferative ) , or camptothecin ( topoisomerase 1 inhibitor ) and after serum withdrawal .
. IGF-1 increased cell survival of HBL100 cells treated with 5-fluorouracil ( antimetabolite ) , methotrexate ( antimetabolite ) , tamoxifen ( antiestrogen / antiproliferative ) , or camptothecin ( topoisomerase 1 inhibitor ) and after serum withdrawal .
. IGF-1 increased cell survival of HBL100 cells treated with 5-fluorouracil ( antimetabolite ) , methotrexate ( antimetabolite ) , tamoxifen ( antiestrogen / antiproliferative ) , or camptothecin ( topoisomerase 1 inhibitor ) and after serum withdrawal .
. IGF-1 increased cell survival of HBL100 cells treated with 5-fluorouracil ( antimetabolite ) , methotrexate ( antimetabolite ) , tamoxifen ( antiestrogen / antiproliferative ) , or camptothecin ( topoisomerase 1 inhibitor ) and after serum withdrawal .
Extracellular MatrixIs associated anatomy of gene productLaminin
Extracellular matrix ( ECM ) is known to influence the apoptotic response of cells ; therefore , the antiapoptotic effect of IGF-1 on breast cancer cells was examined using different ECMs : laminin , collagen IV , or Matrigel .
. IGF-1 increased cell survival of HBL100 cells treated with 5-fluorouracil ( antimetabolite ) , methotrexate ( antimetabolite ) , tamoxifen ( antiestrogen / antiproliferative ) , or camptothecin ( topoisomerase 1 inhibitor ) and after serum withdrawal .
. IGF-1 increased cell survival of HBL100 cells treated with 5-fluorouracil ( antimetabolite ) , methotrexate ( antimetabolite ) , tamoxifen ( antiestrogen / antiproliferative ) , or camptothecin ( topoisomerase 1 inhibitor ) and after serum withdrawal .
LamininMapped frommatrigel
Extracellular matrix ( ECM ) is known to influence the apoptotic response of cells ; therefore , the antiapoptotic effect of IGF-1 on breast cancer cells was examined using different ECMs : laminin , collagen IV , or Matrigel .
. IGF-1 increased cell survival of HBL100 cells treated with 5-fluorouracil ( antimetabolite ) , methotrexate ( antimetabolite ) , tamoxifen ( antiestrogen / antiproliferative ) , or camptothecin ( topoisomerase 1 inhibitor ) and after serum withdrawal .
. IGF-1 increased cell survival of HBL100 cells treated with 5-fluorouracil ( antimetabolite ) , methotrexate ( antimetabolite ) , tamoxifen ( antiestrogen / antiproliferative ) , or camptothecin ( topoisomerase 1 inhibitor ) and after serum withdrawal .
All Topics